[ Price : $8.95]
An IQVIA analysis of novel active substance approvals from 2014 to 2022 in the U.S., EU, and Japan shows the U.S. approves more ne...[ Price : $8.95]
FDA approves a Johnson & Johnson MedTech PMA supplement for expanded indications for the Impella 5.5 with SmartAssist and Impella ...[ Price : $8.95]
Pfizer says data from the Phase 3 PATINA trial demonstrated that adding Ibrance (palbociclib) to current standard-of-care first-li...[ Price : $8.95]
Lawyers on a Food & Drug Law Institute enforcement panel warn that the incoming Trump administration is likely to target and seek ...[ Price : $8.95]
Federal Register notice: FDA announces the revocation of B. Braun Medical emergency use authorizations for three Covid-related dev...[ Price : $8.95]
A Paragon Health Institute white paper suggests an approach to regulating healthcare artificial intelligence that it says builds o...[ Price : $8.95]
Based on FDA feedback, NeuroSense Therapeutics says it will begin a Phase 3 study of PrimeC (ciprofloxacin and celecoxib) for trea...[ Price : $8.95]
CDRH issues an early alert on a Fresenius Kabi high-risk Ivenix large-volume pump issue, the Centers first alert under a new commu...